The Effect of Thiazide, Amiloride and Hypertonic Saline on Urinary Biomarkers in Healthy Subjects

Nephropathy Clinical Trial

— THAM  

Official title:

Effect of Thiazide, Amiloride and Hypertonic Saline on Sodium- and Water Channel Activity in the Nephron in Healthy Subjects Estimated by Urinary Biomarkers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01635231
• Other study ID #: EBP-JMJ-2012-1
• Status: Completed
• Phase: N/A
• First received: June 13, 2012
• Last updated: March 1, 2014
• Start date: July 2012
• Est. completion date: November 2013

Study information

• Verified date: March 2014
• Source: Regional Hospital Holstebro
• Contact: n/a
• Is FDA regulated: No
• Health authority: Denmark: Danish Dataprotection AgencyDenmark: Ethics Committee
• Study type: Interventional

Clinical Trial Summary

Urinary biomarkers (u-NKCC2, u-ENaC-gamma and u-AQP2) reflects the activity of the sodium- and water channels in the human kidney.

Changes in the sodium-and water channel activity can be induced by blocking the sodium channels with diuretics in healthy subjects

Description:

1. Urinary biomarkers (u-NKCC2, u-ENaC-gamma and u-AQP2) reflects the kidneys transport of sodium and water in the nephron.

2. Changes in the sodium-and water channel activity is induced by blocking the NCC channels with thiazide and ENaC channels with amiloride and by intervention with hypertonic NaCl The changes in sodium-and water channels are followed by changes in extracellular and intracellular fluids, central bloodpressure and the plasma concentration of vasoactive hormones.

The purpose of this study is to investigate the changes in urinary biomarkers (u-NKCC2, u-ENaC-gamma and u-AQP2), extra- and intracellular fluid compartments, central bloodpressure and the plasma concentration of Vasoactive hormones in healthy subjects under a) treatment with Amiloride and Thiazide at baseline and b) after and acute infusion with hypertonic saline.

Subjects will be examined on three examination days. Four days prior to the examination days the subjects will consume a standard diet based on amount of sodium and calories and randomized to treatment with either thiazide, amiloride or placebo twice daily for 5 days. On the examination days the subjects receive an infusion with hypertonic saline.

Renal function is measured by renal clearance of 51Cr-EDTA. Urinary biomarkers (u-NKCC2, u-ENaC-gamma and u-AQP2) will be measured to evaluate the activity of water- and sodium channels in the nephron, changes in fluid compartments are measured by body composition monitor. Central blood pressure is measured by sphygmocor.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: November 2013
• Est. primary completion date: September 2013
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• healthy males and females

• age 18-45

• BMI range 18,5-30,0 kg/m2

Exclusion Criteria:

• hypertension (i.e. ambulatory BP > 130 mmHg systolic or/and > 80 mmHg diastolic)

• history or clinical significant signs of heart, lung, liver, kidney, endocrine, brain or neoplastic

• disease.

• alcohol abuse

• drug abuse

• smoking

• pregnancy or nursing

• blood donation within a month prior to examination

• medical treatment apart from oral contraception abnormal blood samples, -ECG and -urine dipstick, drug abuse, alcohol abuse, pregnancy, medication

Study Design

Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Diagnostic

Related Conditions & MeSH terms

• Nephropathy

Intervention

Other:
• hypertonic saline
hypertonic saline 3.0% 7 ml/kg

Locations

Country	Name	City	State
Denmark	Medical Research	Holstebro

Sponsors (1)

Lead Sponsor	Collaborator
Regional Hospital Holstebro

Country where clinical trial is conducted

Denmark, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	urinary biomarkers	Urinary excretion of epithelial sodium channels (ENaC), Sodium-potassium-2chloride transporters (NKCC2) and aquaporin2 channels (AQP2) before, during and after fluid infusion	baseline, 0 hours and 1.5 hours after intervention	No
Secondary	vaso active hormones	plasma concentrations of: renin, Angiotensin II, aldosterone, Vasopressin, ANP and BNP	baseline, 0 hours and 1.5 hours after intervention	No
Secondary	central blood pressure	measured by applanation-tonometry	baseline, 0 hours and 1.5 hours after intervention	No
Secondary	intracellular (ICV)- and extracellular volume (ECV)	change in ICV and EVC from baseline and after intervention measured in liters by body composition monitor (BCM)	baseline, 0 hours and 1.5 hours after intervention	No